Revenue ($USD) : $1,305,300,000
R&D spend : $180,200,000.00
Employees : 2,600
Fiscal year end : 12/31/22
CEO : Jim Hollingshead

Insulet develops wearable automated insulin delivery devices, such as its flagship Omnipod patch pump, which is one of the market leaders in the space.

Insulet became a member of the S&P 500 this year, replacing Silicon Valley Bank in March.

The company also received FDA clearance for a basal-only insulin delivery system this year, expanding the company’s reach within the diabetes patient population. –SW